TOTAL: $22.5M | ||||
Year to Date: $515.37M | ||||
Company |
Partner |
Amt. |
Triggering |
Details (Date) |
Can-Fite |
Seikagaku Corp. (Japan) |
$0.5 |
Milestone payment |
Triggered by enrollment of more than half the patients in a Phase IIb trial of CF101 in rheumatoid arthritis (10/23) |
Curis Inc. |
Genentech Inc. (NYSE:DNA) |
$3 |
Milestone payment |
Triggered by Genentech's filing of an IND to initiate Phase I trials of a small- molecule Hedgehog antagonist for treating cancer (10/5) |
Immunogen |
Sanofi-Aventis SA (France) |
$2 |
Milestone payment |
Triggered by Sanofi's initiation of clinical testing of AVE1642, an antibody that binds to the insulin-like growth factor 1 receptor (10/4) |
Indevus |
Esprit Pharma Inc. |
$10 |
Milestone payment |
Triggered by submission of a new drug appli- cation with the FDA seeking approval of Sanctura for treating overactive bladder (10/18) |
Memory |
F. Hoffmann- La Roche Ltd. (Switzerland) |
$2 |
Milestone payment |
Triggered by Roche's decision to maintain its option to license MEM 3454, the lead compound from their deal on nicotinic alpha-7 receptor agonists for treating neurological disorders (10/31) |
Progenics |
Wyeth Pharmaceuticals |
$5 |
Milestone payment |
Triggered by Progenics' start of a Phase III trial of intravenous methylnaltrexone for treating postoperative ileus (10/25) |
| ||||
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
TEL = Tel Aviv Stock Exchange. |